Prescient advances PTX-100 trial after FDA Fast Track nod, raises $6.8 million for development
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.